Marinus Pharmaceuticals Q4 2020 Earnings Report
Key Takeaways
Marinus Pharmaceuticals reported a net loss of $17.5 million for the fourth quarter of 2020, with research and development expenses increasing to $13.0 million and general and administrative expenses increasing to $6 million. The company ended the year with $140.0 million in cash, cash equivalents and investments.
Marinus remains on track to submit a new drug application to the FDA for ganaxolone in CDKL5 Deficiency Disorder.
Active enrollment continues in the Phase 3 RSE trial.
Oral programs are advancing and expanding.
The company raised $70 million in December and ended the year with $140 million of cash on hand.
Marinus Pharmaceuticals
Marinus Pharmaceuticals
Forward Guidance
Marinus projects spend in the range of $18 to $20 million per quarter in 2021, offset by approximately $2 to $3 million per quarter from BARDA in 2021. This spend could increase in 3Q with the initiation of the TSC trial and ongoing expenses associated with the RAISE trial.